Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | CDC25B | P30305 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 6/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ALPL | P05186 | 1/20 | 0.40 |
| ▸ | XPO1 | O14980 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
| ▸ | FOS | P01100 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2874452 | 0.81 | KMT2A (0.57) | NPSR1CDC25BHPGDALDH1A1HSD17B10 | |
| SCHEMBL7497667 | 0.78 | NPSR1 (0.56) | NPSR1L3MBTL1CDC25BHPGDALDH1A1 | |
| SCHEMBL6337094 | 0.77 | ALDH1A1 (0.48) | CDC25BHPGDALDH1A1HSD17B10AURKA | |
| SCHEMBL17221098 | 0.72 | ALDH1A1 (0.52) | NPSR1L3MBTL1HPGDALDH1A1HSD17B10 | |
| SCHEMBL2874155 | 0.72 | PDE4D (0.58) | NPSR1L3MBTL1CDC25BHPGDALDH1A1 | |
| SCHEMBL9941259 | 0.70 | KDM4E (0.50) | L3MBTL1CDC25BHPGDALDH1A1HSD17B10 | |
| SCHEMBL31378500 | 0.70 | NPSR1 (0.59) | NPSR1L3MBTL1HPGDALDH1A1HSD17B10 | |
| SCHEMBL4063809 | 0.69 | L3MBTL1 (0.62) | NPSR1L3MBTL1HPGDALDH1A1HSD17B10 | |
| SCHEMBL1455540 | 0.69 | ALDH1A1 (0.65) | NPSR1L3MBTL1HPGDALDH1A1HSD17B10 | |
| SCHEMBL13398524 | 0.68 | NPSR1 (0.51) | NPSR1L3MBTL1HPGDALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324216-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324216-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-7842693-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842693-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-20100240618-A1 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100240618-A1 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-7589199-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-7589199-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| EP-1531822-B1 | 1-ARYL-4-SUBSTITUTED PIPERAZINE DERIVATIVES FOR USE AS CCR1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION AND IMMUNE DISORDERS | CHEMOCENTRYX INC (US) | 2009-08-05 | — | — | EP | disclosed |
| EP-1691810-A4 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX INC (US) | 2009-07-01 | — | — | EP | disclosed |
| US-7157464-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157464-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2007-01-02 | — | — | US | disclosed |
| EP-1691810-A1 | SUBSTITUTED PIPERAZINES | ChemoCentryx Inc (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20060106218-A1 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2006-05-18 | — | — | US | disclosed |
| US-20050256130-A1 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2005-11-17 | — | — | US | disclosed |
| WO-2005056015-A1 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX, INC. (US) | 2005-06-23 | — | — | WO | disclosed |
| EP-1531822-A1 | 1-ARYL-4-SUBSTITUTED PIPERAZINE DERIVATIVES FOR USE AS CCR1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION AND IMMUNE DISORDERS | Chemocentryx, Inc. (US) | 2005-05-25 | — | — | EP | disclosed |
| US-20040162282-A1 | Substituted piperazines | CHEMOCENTRYX, INC. | 2004-08-19 | — | — | US | disclosed |
| US-20040082571-A1 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2004-04-29 | — | — | US | disclosed |
| WO-2003105853-A1 | 1-ARYL-4-SUBSTITUTED PIPERAZINES DERIVATIVES FOR USE AS CCR1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION AND IMMUNE DISORDERS | CHEMOCENTRYX, INC. (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082571-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | NPSR1 469/4885L3MBTL1 1517/4885CDC25B 3126/4885 |
| US-20060106218-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | NPSR1 380/4885L3MBTL1 1589/4885CDC25B 3110/4885 |
| US-20050256130-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | NPSR1 380/4885L3MBTL1 1589/4885CDC25B 3110/4885 |
| US-20040162282-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | NPSR1 469/4885L3MBTL1 1517/4885CDC25B 3126/4885 |
| US-20100240618-A1 | SUBSTITUTED PIPERAZINES | CCR1, CCR3, CCRL2 | NPSR1 380/4885L3MBTL1 1589/4885CDC25B 3110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.